X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6999) 6999
Publication (650) 650
Newsletter (108) 108
Book Review (91) 91
Book Chapter (37) 37
Newspaper Article (30) 30
Magazine Article (23) 23
Trade Publication Article (7) 7
Data Set (4) 4
Dissertation (4) 4
Conference Proceeding (3) 3
Transcript (2) 2
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5825) 5825
male (3623) 3623
ribavirin (3543) 3543
female (3518) 3518
hepatitis c, chronic - drug therapy (3322) 3322
index medicus (3184) 3184
ribavirin - administration & dosage (3118) 3118
antiviral agents - administration & dosage (3104) 3104
middle aged (2987) 2987
drug therapy, combination (2783) 2783
adult (2732) 2732
antiviral agents - therapeutic use (2700) 2700
hepatitis c (2436) 2436
ribavirin - therapeutic use (2353) 2353
treatment outcome (2220) 2220
interferon-alpha - administration & dosage (2218) 2218
gastroenterology & hepatology (1811) 1811
interferon (1755) 1755
hepacivirus - genetics (1699) 1699
hepatitis c virus (1643) 1643
recombinant proteins (1643) 1643
interferon-alpha - therapeutic use (1632) 1632
genotype (1533) 1533
antiviral agents - adverse effects (1378) 1378
aged (1353) 1353
polyethylene glycols - administration & dosage (1255) 1255
therapy (1202) 1202
hepatitis c, chronic - virology (1173) 1173
hepatitis c - drug therapy (1163) 1163
ribavirin - adverse effects (1094) 1094
virus-infection (1064) 1064
infectious diseases (1060) 1060
hepatitis (1058) 1058
plus ribavirin (1046) 1046
infection (1040) 1040
hepacivirus - drug effects (995) 995
drug therapy (986) 986
health aspects (947) 947
interferon-alpha - adverse effects (944) 944
polyethylene glycols - therapeutic use (922) 922
pharmacology & pharmacy (882) 882
care and treatment (880) 880
viral load (875) 875
virology (855) 855
antiviral agents (776) 776
dosage and administration (741) 741
drug administration schedule (727) 727
rna, viral - blood (695) 695
hepatitis c, chronic - complications (664) 664
biological response modifiers (638) 638
infections (635) 635
hcv (622) 622
research (618) 618
risk factors (604) 604
animals (603) 603
sustained virological response (600) 600
combination therapy (598) 598
pegylated interferon (595) 595
recombinant proteins - administration & dosage (591) 591
virus diseases (583) 583
immunology (582) 582
viruses (560) 560
chronic hepatitis-c (557) 557
time factors (533) 533
analysis (527) 527
liver (522) 522
retrospective studies (520) 520
chronic hepatitis c (513) 513
adolescent (501) 501
genetic aspects (499) 499
polyethylene glycols - adverse effects (491) 491
recombinant proteins - therapeutic use (483) 483
dose-response relationship, drug (479) 479
antiviral agents - pharmacology (475) 475
medicine, general & internal (475) 475
sofosbuvir (473) 473
cirrhosis (472) 472
virus (468) 468
young adult (465) 465
microbiology (463) 463
combination (462) 462
hepacivirus - isolation & purification (451) 451
peginterferon alpha-2a (448) 448
peginterferon (447) 447
prospective studies (438) 438
initial treatment (420) 420
telaprevir (420) 420
recurrence (413) 413
patients (408) 408
genotype & phenotype (402) 402
gastroenterology and hepatology (399) 399
hiv infections - complications (399) 399
rna (390) 390
hepatitis c - virology (373) 373
interferons - administration & dosage (369) 369
hepatology (368) 368
efficacy (366) 366
antiviral therapy (364) 364
follow-up studies (364) 364
genotypes (364) 364
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6597) 6597
Spanish (87) 87
Japanese (85) 85
French (84) 84
German (84) 84
Russian (56) 56
Chinese (45) 45
Polish (38) 38
Korean (21) 21
Hungarian (20) 20
Croatian (14) 14
Italian (14) 14
Czech (10) 10
Serbian (9) 9
Portuguese (8) 8
Dutch (4) 4
Turkish (4) 4
Arabic (3) 3
Slovak (3) 3
Swedish (3) 3
Danish (2) 2
Hebrew (2) 2
Norwegian (2) 2
Bosnian (1) 1
Finnish (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1711 - 1720
Background. Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the... 
real-world | HCV | HIV | DAA | INFECTIOUS DISEASES | HIV/HCV | LEDIPASVIR-SOFOSBUVIR | CHRONIC HEPATITIS-C | MICROBIOLOGY | COINFECTED INDIVIDUALS | IMMUNOLOGY | INFECTION | COHORT | Uridine Monophosphate - administration & dosage | Anilides - therapeutic use | Hepatitis C - drug therapy | Coinfection - drug therapy | Veterans | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Practice Patterns, Physicians | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Female | Fluorenes - administration & dosage | Hepatitis C - complications | Registries | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Administration, Oral | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Coinfection - virology | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Cohort Studies | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis C | HIV infection
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 4, pp. 770 - 776
Background & Aims HCV requires host lipid metabolism for replication, and apolipoproteins have been implicated in the response to treatment. Methods We... 
Gastroenterology and Hepatology | Quantitative trait loci | IL28B | Lipid metabolism | Hepatitis C virus | Apolipoproteins | PARTICLES | BETA-2-GLYCOPROTEIN-I | RIBAVIRIN | PEGYLATED INTERFERON-ALPHA | LIPOPROTEIN-LIPASE | HCV INFECTION | GENETIC-VARIATION | LOW-DENSITY | SERUM-LIPIDS | GASTROENTEROLOGY & HEPATOLOGY | GENOME-WIDE ASSOCIATION | Coinfection | Hepatitis C - drug therapy | Humans | Middle Aged | Male | Viral Load | beta 2-Glycoprotein I - blood | HIV Infections - immunology | Hepatitis C - immunology | Interleukins - genetics | Ribavirin - administration & dosage | Adult | Female | Hepacivirus - physiology | Hepatitis C - complications | Hepacivirus - drug effects | Virus Replication - drug effects | Hepatitis C - genetics | Treatment Outcome | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | beta 2-Glycoprotein I - genetics | HIV Infections - complications | HIV Infections - drug therapy | Hepatitis C - physiopathology | Aged | Polymorphism, Single Nucleotide | Genetic aspects | Health aspects | beta 2-Glycoprotein I/blood | Virus Replication/drug effects | HIV Infections/immunology | HIV Infections/drug therapy | Life Sciences | beta 2-Glycoprotein I/genetic | Immunology | Hepatitis C/complications Hepatitis | Polyethylene Glycols/administration & dosage | Interferon-alpha/administration & dosage | C/physiopathology Humans | Interleukins/genetics | Hepacivirus/physiology | C/drug therapy Hepatitis | C/immunology Hepatitis | HIV Infections/complications | Ribavirin/administration & dosage | Hepacivirus/drug effects | Antiviral Agents/administration & dosage | C/genetics Hepatitis
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Journal Article
Expert Review of Anti-Infective Therapy, ISSN 1478-7210, 2014, Volume 12, Issue 7, pp. 763 - 773
About 2% of the world's population is estimated to be chronically infected with hepatitis C virus (HCV). These chronic carriers are at risk of developing liver... 
Daclatasvir | MK-8742 | Ombitasvir | Interferon-free | Ledipasvir | MK-5172 | Asunaprevir | ABT-450 | Sofosbuvir | Dasabuvir | CONTROLLED-TRIAL | PLUS RIBAVIRIN | LIVER-TRANSPLANTATION | ombitasvir | asunaprevir | HCV INFECTION | daclatasvir | interferon-free | ledipasvir | sofosbuvir | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | TREATMENT OPTIONS | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | dasabuvir | CHRONIC VIRAL-HEPATITIS | DISEASE PROGRESSION | Uridine Monophosphate - administration & dosage | Quinoxalines - adverse effects | Anilides - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Carbamates - administration & dosage | Uracil - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Hepatitis C - prevention & control | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Disease Eradication | Benzofurans - therapeutic use | Quinoxalines - administration & dosage | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Anilides - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Hepacivirus | Isoquinolines - administration & dosage | Drug Combinations | Sulfonamides - administration & dosage | Uracil - analogs & derivatives
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article